SCHEMBL2276257

SCHEMBL2276257

O=C(O)c1ccnc(C(=O)O)c1.[Zn]

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5C P41229 6/20 0.96
KDM4E B2RXH2 5/20 0.96
KDM4A O75164 5/20 0.96
FTO Q9C0B1 4/20 0.96
KDM6B O15054 4/20 0.96
KDM2A Q9Y2K7 4/20 0.96
KDM3A Q9Y4C1 4/20 0.96
KDM5B Q9UGL1 4/20 0.96
ALDH1A1 P00352 3/20 0.96
ALKBH5 Q6P6C2 3/20 0.96
KDM4C Q9H3R0 3/20 0.96
TET3 O43151 1/20 0.96
BBOX1 O75936 1/20 0.96
MAPT P10636 1/20 0.96
KDM5A P29375 1/20 0.96
ASPH Q12797 1/20 0.96
KDM4D Q6B0I6 1/20 0.96
TET2 Q6N021 1/20 0.96
KDM7A Q6ZMT4 1/20 0.96
KDM8 Q8N371 1/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72377 0.98 KDM5C (1.00) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL29382783 0.98 KDM5C (1.00) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL28454743 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
Hydrochloric Acid SCHEMBL9361001 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL27779659 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
Hydrochloric Acid SCHEMBL10778857 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL9585979 0.96 FTO (0.96) KDM5CKDM4EKDM4AFTOKDM6B
Water SCHEMBL2650345 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL9585966 0.96 KDM5C (0.96) KDM5CKDM4EKDM4AFTOKDM6B
SCHEMBL28460401 0.87 KDM5C (0.79) KDM5CKDM4EKDM4AFTOKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
CN-100411617-C Method of treating symptons of common cold allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2008-08-20 CN disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
CN-1717227-A Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM AS (DK) 2006-01-04 CN disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
EP-1307189-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT Immupharm APS (DK) 2003-05-07 EP disclosed
WO-2002009699-A2 METHOD OF TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2002-02-07 WO disclosed
EP-0433457-B1 ANTIPRURITIC COMPOSITION SHISEIDO CO LTD (JP) 1994-10-19 EP disclosed
US-5219847-A Antipruritic composition SHISEIDO COMPANY, LTD. (JP) 1993-06-15 US disclosed
EP-0433457-A1 ANTIPRURITIC COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM5C 2408/4885KDM4E 4189/4885KDM4A 3220/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM5C 2408/4885KDM4E 4189/4885KDM4A 3220/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP KDM5C 212/4885KDM4E 430/4885KDM4A 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.